Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is an open-label, Phase II interventional study in order to assess efficacy and safety of single agent ublituximab as initial therapy for FL (Follicular lymphoma) and MZL (Marginal zone lymphoma ) with response driven addition of umbralisib for suboptimal response.
Epistemonikos ID: cd94f7b5038ae0808c06540717dad6f820c40062
First added on: May 07, 2024